KR20210102192A - 골수증식성 장애를 치료하는 방법 - Google Patents

골수증식성 장애를 치료하는 방법 Download PDF

Info

Publication number
KR20210102192A
KR20210102192A KR1020217012234A KR20217012234A KR20210102192A KR 20210102192 A KR20210102192 A KR 20210102192A KR 1020217012234 A KR1020217012234 A KR 1020217012234A KR 20217012234 A KR20217012234 A KR 20217012234A KR 20210102192 A KR20210102192 A KR 20210102192A
Authority
KR
South Korea
Prior art keywords
thiamine
patient
compound
myelofibrosis
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217012234A
Other languages
English (en)
Korean (ko)
Inventor
티마라 베리
존 후드
카트리오나 자미에슨
커티스 엘. 스크라이브너
Original Assignee
임팩트 바이오메디신스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69950867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20210102192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 임팩트 바이오메디신스, 인코포레이티드 filed Critical 임팩트 바이오메디신스, 인코포레이티드
Priority to KR1020257037570A priority Critical patent/KR20250164332A/ko
Publication of KR20210102192A publication Critical patent/KR20210102192A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020217012234A 2018-09-25 2019-09-24 골수증식성 장애를 치료하는 방법 Ceased KR20210102192A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257037570A KR20250164332A (ko) 2018-09-25 2019-09-24 골수증식성 장애를 치료하는 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862736369P 2018-09-25 2018-09-25
US62/736,369 2018-09-25
US201862783076P 2018-12-20 2018-12-20
US62/783,076 2018-12-20
PCT/US2019/052608 WO2020068755A1 (en) 2018-09-25 2019-09-24 Methods of treating myeloproliferative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257037570A Division KR20250164332A (ko) 2018-09-25 2019-09-24 골수증식성 장애를 치료하는 방법

Publications (1)

Publication Number Publication Date
KR20210102192A true KR20210102192A (ko) 2021-08-19

Family

ID=69950867

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217012234A Ceased KR20210102192A (ko) 2018-09-25 2019-09-24 골수증식성 장애를 치료하는 방법
KR1020257037570A Pending KR20250164332A (ko) 2018-09-25 2019-09-24 골수증식성 장애를 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257037570A Pending KR20250164332A (ko) 2018-09-25 2019-09-24 골수증식성 장애를 치료하는 방법

Country Status (14)

Country Link
US (2) US20220031699A1 (https=)
EP (1) EP3856169A4 (https=)
JP (2) JP2022502492A (https=)
KR (2) KR20210102192A (https=)
CN (1) CN113286584A (https=)
AU (1) AU2019346521B2 (https=)
BR (1) BR112021005518A2 (https=)
CL (1) CL2021000744A1 (https=)
IL (1) IL281736A (https=)
MA (1) MA53741A (https=)
MX (2) MX2021003450A (https=)
MY (1) MY209349A (https=)
SG (1) SG11202103019WA (https=)
WO (1) WO2020068755A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
KR20250134004A (ko) * 2018-09-25 2025-09-09 임팩트 바이오메디신스, 인코포레이티드 골수증식성 장애를 치료하는 방법
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
US20240058336A1 (en) 2020-12-16 2024-02-22 Impact Biomedicines, Inc. Dosing of fedratinib
MX2023009858A (es) 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
WO2023044297A1 (en) 2021-09-14 2023-03-23 Impact Biomedicines, Inc. Fedratinib for treating myeloproliferative disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US20090093009A1 (en) * 2007-10-09 2009-04-09 Sum Chan Mass spectrometry method for measuring thiamine in body fluid
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US20130102624A1 (en) * 2011-05-19 2013-04-25 John V. Schloss Early detection of thiamine deficiency
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
EP3099677A4 (en) * 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CN108348578B (zh) * 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
KR20250134004A (ko) 2018-09-25 2025-09-09 임팩트 바이오메디신스, 인코포레이티드 골수증식성 장애를 치료하는 방법
FR3092581A1 (fr) 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Also Published As

Publication number Publication date
WO2020068755A1 (en) 2020-04-02
MX2023013844A (es) 2023-12-08
JP2024161416A (ja) 2024-11-19
AU2019346521A1 (en) 2021-05-20
JP2022502492A (ja) 2022-01-11
SG11202103019WA (en) 2021-04-29
EP3856169A1 (en) 2021-08-04
KR20250164332A (ko) 2025-11-24
MY209349A (en) 2025-07-03
EP3856169A4 (en) 2022-06-29
AU2019346521B2 (en) 2025-05-08
BR112021005518A2 (pt) 2021-06-29
IL281736A (en) 2021-05-31
MX2021003450A (es) 2021-07-16
US11400092B2 (en) 2022-08-02
MA53741A (fr) 2021-08-04
US20220133724A1 (en) 2022-05-05
CN113286584A (zh) 2021-08-20
CL2021000744A1 (es) 2021-10-08
US20220031699A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
US11400092B2 (en) Methods of treating myeloproliferative disorders
Hart et al. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer
Verstovsek Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
CN120514709A (zh) 用于治疗癌症的menin-mll抑制剂
US20220133751A1 (en) Methods of treating myeloproliferative disorders
JP2025098099A (ja) ブルトン型チロシンキナーゼ阻害剤の投薬
US20130096169A1 (en) Treatment of cancer with bio and chemotherapy
Khorramdelazad et al. A1, an innovative fluorinated CXCR4 inhibitor, redefines the therapeutic landscape in colorectal cancer
Al‐Kali et al. A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
EA021951B1 (ru) Противораковая комбинация
WO2019141235A1 (zh) 治疗肝癌的药物组合和方法
CN113730572A (zh) 含有抗egfr抗体或其片段的联合用药物
Nouri et al. AKT inhibition sensitizes to polo-like kinase 1 inhibitor onvansertib in prostate cancer
HK40049559A (en) Methods of treating myeloproliferative disorders
EA051859B1 (ru) Способы лечения миелопролиферативных расстройств
KR20260026127A (ko) 대장암 또는 돌연변이성 대장암 치료를 위한 mek 억제제 및 pkl1 억제제의 병용 요법
EA048287B1 (ru) Способы лечения миелопролиферативных расстройств
Harrison et al. RARE-63. MULTICENTRIC GLIOMA IN OLLIER DISEASE: A CASE REPORT AND REVIEW OF THE LITERATURE
Kuzmina et al. CML-598: Clinical Significance of Somatic Mutations in Chronic Myeloid Leukemia Patients on Asciminib Therapy
KR101192097B1 (ko) Ａ3 아데노신 수용체 효능제를 포함하는 대장암 치료용 약제학적 조성물
HK40118757A (zh) 用於治疗癌症的包含gdc-6036和gdc-0077的组合疗法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104